EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Claudin-9 (CLDN9) promotes gastric cancer progression by enhancing the glycolysis pathway and facilitating PD-L1 lactylation to suppress CD8+ T cell anti-tumor immunity

Xingbin Hu, Wenhao Ouyang, Haizhu Chen, Zhihong Liu, Zijia Lai, Herui Yao

Cancer Pathogenesis and Therapy · 2025-05 · 3 (3) · 253-266

DOI: 10.1016/j.cpt.2024.09.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Pathogenesis and Therapy, 2025-05. Verfasst von Xingbin Hu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Centre, Department of Medical Oncology, Phase I …. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: China Postdoctoral Science Foundation, Basic and Applied Basic Research Foundation of Guangdong Province, Science and Technology Planning Project of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Gastric cancer (GC) is a common malignancy characterized by the absence of reliable prognostic indicators and effective therapeutic targets. Claudin-9 (CLDN9) has been demonstrated to be upregulated in various cancers. However, its prognostic value, biological function, and regulatory mechanisms in GC remain unclear. Therefore, this study aimed to elucidate the role of CLDN9 in GC progression and its underlying mechanisms.

Methods

We utilized consensus cluster, random survival forest, and multivariate Cox regression analyses to identify CLDN9 in GC. Subsequently, we evaluated the mRNA and protein levels of CLDN9 in GC using quantitative real-time polymerase chain reaction (PCR) (qRT-PCR), Western blotting (WB), and immunohistochemistry (IHC). Furthermore, the role of CLDN9 in GC progression was investigated using a series of functional in vivo and in vitro experiments. Finally, we elucidated the molecular mechanisms of CLDN9 using bioinformatics, molecular biology, animal models, and patient tissue specimens.

Results

Two GC subtypes with survival and functional differences were identified based on glycolytic metabolic genes in the Cancer Genome Atlas (TCGA)- Stomach adenocarcinoma (STAD) dataset. A prognostic risk score was calculated using seven genes to assess the overall survival (OS) in GC. Using random survival forest and multivariate Cox analyses, we identified CLDN9 as the key gene linked to the glycolytic subtype and prognosis of GC. CLDN9 expression was significantly upregulated in patients with GC as well as in GC cells. CLDN9 knockdown inhibited tumor proliferation, invasion, and metastasis both in vivo and in vitro. Mechanistically, CLDN9 was found to regulate lactate dehydrogenase A (LDHA) expression and promote glycolytic metabolism by activating the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/hypoxia-inducible factor 1-alpha (HIF1α) signaling pathway. Additionally, lactate, a glycolytic metabolite, enhanced programmed cell death ligand 1 (PD-L1) lactylation and stability, which suppressed anti-tumor immunity in CD8+ T cells, thereby contributing to GC progression.

Conclusions

CLDN9 expression is associated with GC development and progression. Mechanistically, CLDN9 enhances the glycolysis pathway and facilitates PD-L1 lactylation through the PI3K/AKT/HIF1α signaling pathway, thereby suppressing anti-tumor immunity in CD8+ T cells. CLDN9 has the potential to serve as a novel prognostic marker and therapeutic target for GC.

Schlagwörter

Stichwörter der Autor:innen

CLDN9Gastric cancerGlycolysisImmune evasionLactylationPD-L1

Autor:innen und Institutionen

  • Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Centre, Department of Medical Oncology, Phase I Clinical Trial Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen Univ…
  • Department of Medical Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510120, China.
  • Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510120, China.
  • Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.

Förderung

  • China Postdoctoral Science Foundation
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Science and Technology Planning Project of Guangdong Province
  • National Natural Science Foundation of China

Zitieren

APA

Hu, X., Ouyang, W., Chen, H., Liu, Z., Lai, Z., & Yao, H. (2025). Claudin-9 (CLDN9) promotes gastric cancer progression by enhancing the glycolysis pathway and facilitating PD-L1 lactylation to suppress CD8+ T cell anti-tumor immunity. Cancer Pathogenesis and Therapy, 3(3), 253-266. https://doi.org/10.1016/j.cpt.2024.09.006

Vancouver

Hu X, Ouyang W, Chen H, Liu Z, Lai Z, Yao H. Claudin-9 (CLDN9) promotes gastric cancer progression by enhancing the glycolysis pathway and facilitating PD-L1 lactylation to suppress CD8+ T cell anti-tumor immunity. Cancer Pathogenesis and Therapy. 2025;3(3):253-266. doi:10.1016/j.cpt.2024.09.006

BibTeX
@article{Hu2025,
  author = {Hu, Xingbin and Ouyang, Wenhao and Chen, Haizhu and Liu, Zhihong and Lai, Zijia and Yao, Herui},
  title = {Claudin-9 (CLDN9) promotes gastric cancer progression by enhancing the glycolysis pathway and facilitating PD-L1 lactylation to suppress CD8+ T cell anti-tumor immunity},
  journal = {Cancer Pathogenesis and Therapy},
  year = {2025},
  volume = {3},
  number = {3},
  pages = {253--266},
  doi = {10.1016/j.cpt.2024.09.006}
}
Kostenlos starten →